{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:44:02Z","timestamp":1776231842832,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Extracranial malignant rhabdoid tumors (MRT) and rhabdoid tumors of the kidney (RTK) are rare pediatric solid tumors characterized by aggressive behavior and poor prognosis. Case reports have demonstrated successful outcomes using ifosfamide-containing chemotherapy regimens, leading some clinicians to incorporate this alkylating agent into treatment plans. We assessed our institutional experience treating MRT and RTK using ifosfamide-containing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifteen patients with histologically confirmed MRT or RTK and loss of INI1 who were treated at Children\u2019s National Hospital (CNH) between 2009 and 2025 were reviewed retrospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age at diagnosis was 16 months (range: 3\u2013171 months). Eleven patients (73.3%) had MRT and four (26.7%) had RTK. Treatment involved multimodal therapy, including surgical resection when feasible, radiation therapy, and intensive chemotherapy. Eleven patients received regimens including ifosfamide, in some cases with higher-dose cyclophosphamide compared to recent Children\u2019s Oncology Group and European Soft Tissue Sarcoma Study Group protocols. Three-year event-free survival (EFS) and overall survival (OS) were 42.4% (95% CI: 22.7-79.3%) and 40.4% (95% CI: 20.8-78.5%), respectively. No significant difference in 3-year EFS was observed with ifosfamide (43.6%, 95% CI: 21.8-87.4%) versus without ifosfamide (37.5%, 95% CI: 8.4-100%; p=0.85). Second and third-line treatment regimens included tazemetostat (n=3), temozolomide\/irinotecan +\/- vincristine (n=3), alisertib (n=1), and cemiplimab (n=1); however, no responses were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ifosfamide-containing regimens did not appear to improve outcomes for MRT or RTK. Novel, targeted therapeutic strategies are urgently needed to improve survival for patients with rhabdoid tumor, particularly those with stage III\/IV disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1785130","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:45:03Z","timestamp":1776228303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of extracranial rhabdoid tumor with intensive ifosfamide-containing chemotherapy regimens"],"prefix":"10.3389","volume":"16","author":[{"given":"Jillian P.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liny","family":"John","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aerang","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly J.","family":"Meany","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy B.","family":"Hont","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Frantz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Dome","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Division of Pediatric Oncology, Children\u2019s National Hospital","place":["Washington, DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70088-3","article-title":"Extracranial rhabdoid tumors: what we have learned so far and future directions","volume":"14","author":"Brennan","year":"2013","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1097\/00000478-198906000-00001","article-title":"Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms\u2019 Tumor Study Pathology Center","volume":"13","author":"Weeks","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(81)80050-0","article-title":"Ultrastructure of Malignant rhabdoid tumor of the kidney","volume":"12","author":"Haas","year":"1981","journal-title":"Hum Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2014.04.004","article-title":"Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth","volume":"207","author":"Kim","year":"2014","journal-title":"Cancer Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13173","article-title":"Oncogenic roles of SMARCB1\/INI1 and its deficient tumors","volume":"108","author":"Kohashi","year":"2017","journal-title":"Cancer Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30979","article-title":"Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric Malignancies","volume":"71","author":"Andres","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/pbc.22231","article-title":"Clinical and pathological features of pediatric Malignant rhabdoid tumors","volume":"54","author":"Morgenstern","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.02.027","article-title":"Outcome of extracranial Malignant rhabdoid tumors in children registered in the European Pediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study\u2014EpSSG NRSTS 2005","volume":"60","author":"Brennan","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2021.10.025","article-title":"Extracranial rhabdoid tumors: Results of a SFCE series of patients treated with a dose compression strategy according to European Pediatric Soft tissue sarcoma Study Group recommendations","volume":"161","author":"Enault","year":"2021","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31490","article-title":"Rhabdoid tumor of the kidney and soft tissues: results from national wilms tumor study\u20105 and children\u2019s oncology group study AREN0321","volume":"72","author":"Geller","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.00.8110","article-title":"Rhabdoid tumor of the kidney in the national wilms\u2019 Tumor study: age at diagnosis as a prognostic factor","volume":"23","author":"Tomlinson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092185","article-title":"Infants and newborns with atypical teratoid rhabdoid tumors (ATRT) and extracranial Malignant rhabdoid tumors (eMRT) in the EU-RHAB registry: A unique and challenging population","volume":"14","author":"Nemes","year":"2022","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/pbc.22285","article-title":"Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with Malignant rhabdoid tumors","volume":"54","author":"Sultan","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26746","article-title":"High-dose treatment for Malignant rhabdoid tumor of the kidney: No evidence for improved survival-The Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie (GPOH) experience","volume":"65","author":"Furtw\u00e4ngler","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200206000-00012","article-title":"Treatment of metastatic rhabdoid tumor of the kidney","volume":"24","author":"Wagner","year":"2002","journal-title":"J Pediatr Hematology\/Oncology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199901000-00012","article-title":"Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: case report and review","volume":"21","author":"Waldron","year":"1999","journal-title":"J Pediatr Hematology\/Oncology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000212901.84146.5a","article-title":"Treatment of stage IV Malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report","volume":"28","author":"Yamamoto","year":"2006","journal-title":"J Pediatr Hematology\/Oncology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25093","article-title":"High dose alkylator therapy for extracranial Malignant rhabdoid tumors in children","volume":"61","author":"Venkatramani","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01055-1","article-title":"Updated favorable-histology Wilms tumor risk stratification: rationale for future Children\u2019s Oncology Group clinical trials","volume":"22","author":"Benedetti","year":"2025","journal-title":"Nat Rev Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/13577140120048890","article-title":"The intergroup rhabdomyosarcoma study group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols","volume":"5","author":"Raney","year":"2001","journal-title":"Sarcoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.22541\/au.167515256.64253518\/v1","article-title":"Tolerability of ifosfamide\u2010containing regimen in patients with high\u2010risk renal and INI\u20101\u2010deficient tumors","volume":"70","author":"Wong","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumors: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3089","article-title":"Genomic and immunologic characterization of INI1-deficient pediatric cancers","volume":"26","author":"Forrest","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac151","article-title":"Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid\/rhabdoid tumor","volume":"25","author":"Upadhyaya","year":"2023","journal-title":"Neuro-oncology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0416","article-title":"Clinical and prognostic characteristics of 53 cases of extracranial Malignant rhabdoid tumor in children. A single-institute experience from 2007 to 2017","volume":"24","author":"Cheng","year":"2019","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/pbc.22831","article-title":"Spectrum of SMARCB1\/INI1 mutations in familial and sporadic rhabdoid tumors","volume":"56","author":"Eaton","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1038\/s41467-023-43498-3","article-title":"SMARCB1 loss activates patient-specific distal oncogenic enhancers in Malignant rhabdoid tumors","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-021-00229-1","article-title":"Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group","volume":"20","author":"Fr\u00fchwald","year":"2021","journal-title":"Familial Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/pbc.24141","article-title":"Epidemiology of rhabdoid tumors of early childhood","volume":"60","author":"Heck","year":"2012","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:45:06Z","timestamp":1776228306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1785130"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1785130","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1785130"}}